RecruitingNot ApplicableNCT04843865
TCM as an Adjuvant Treatment in Breast Cancer Patients
A Systemic Approach to Study the Traditional Chinese Medicine as an Adjuvant Treatment in Breast Cancer Patients
Sponsor
Universiti Tunku Abdul Rahman
Enrollment
30 participants
Start Date
Apr 22, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
Chinese herbs can alleviates the side effects caused by conventional treatment in breast cancer patients and affects the syndrome element differentiation by altering the specific set of proteomes at specific time point of treatment.
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria12
- Postmenopausal women as determined by cessation of menses for at least 1 year or FSH\>20 mIU/mL
- Histology confirmed stage 2 to 3 hormone-receptor positive breast cancer patient
- Currently taking letrozole for at least 1 month
- Reported ongoing musculoskeletal pain or stiffness, which started or worsened after initiation of letrozole
- Had a baseline average pain score over the past week on the Brief Pain Inventory Short Form (BPI-SF) of ≥4 points on a scale of 0 to 10.
- Completed all indicated surgery, chemotherapy and radiation therapy
- Agreed to take prescribed Chinese herbs
- No evidence of distant metastasis
- Follow-up for the duration of the study
- No acute disease in the past month
- Able to communicate to practitioner and interviewer
- Willing to give informed consent
Exclusion Criteria12
- Pregnant or nursing woman or woman of childbearing potential without effective method of birth control.
- Patients who default subsequent follow-up/ has irregular follow-up.
- Patients who directly involved in other study at the same time.
- History of non-compliance to medical regime and patients who are unwilling or unable to comply with the protocol.
- Bedridden and/ or cancer metastasis to bone/ lung.
- Concurrent infection requiring intravenous antibiotics
- History of allergy to Chinese herbs
- Had previously received Chinese herbs for their AI-induced musculoskeletal symptoms
- Had received Chinese herbs within one month prior to study entry
- Current use of steroids or narcotics for pain relief within the past 2 weeks
- Subjects with acute onset of a chronic illness or with acute disease in the past month or had pre-existing chronic diseases
- Patients with concomitant severe illness or metastatic disease (poorly controlled hypertension, hypothyroidism, diabetes mellitus, liver diseases, osteoarthritis, rheumatoid arthritis, gout or neuropathic arthropathy, autoimmune or inflammatory joint disease, bone fracture, stroke)
Interventions
DIETARY_SUPPLEMENTChinese Herbs
Chinese Herbs
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04843865
Related Trials
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer
NCT073490692 locations
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
NCT074245475 locations
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
NCT0722226712 locations
Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients' Derived Organoids
NCT050073791 location
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828763 locations